Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer
Financing supports Ona's transition to a clinical-stage company and delivery of key clinical and regulatory milestones
BARCELONA, Spain, June 04, 2026 (GLOBE NEWSWIRE) -- Ona Therapeutics ("Ona"), a global biopharmaceutical company pioneering first-in-class antibody-drug conjugates (ADCs) to address treatment-resistant cancers, today announced the closing of an oversubscribed $86.6 million Series B financing. The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life Sciences, Asabys Partners, Bpifrance, as part of the InnoBio investment strategy, CDTI through SICC Innvierte, FundPlus NV and Ysios Capital.
The proceeds will be used to advance the clinical development of Ona's lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona's pipeline in indications with significant unmet need. Ona Therapeutics currently retains full worldwide commercial rights to all its assets.
Valerie Vanhooren, PhD, Co-Founder and Chief Executive Officer at Ona Therapeutics, said: "The oversubscribed Series B marks an important step to advancing ONA-255 toward clinical proof of concept in breast cancer, while progressing early clinical development activities for ONA-389 in colorectal cancer. We are proud to have assembled a high-quality syndicate of investors who share our conviction in the differentiated science behind Ona's novel targets and their potential to address drug resistance. Supported by a highly experienced and talented team, this financing strengthens our commitment to tackling hard-to-treat cancers through meaningful innovation and addressing the significant unmet need faced by patients with limited treatment options."
Jose Mesa, Partner at Columbus Venture ...
